| Mr Norman E Pahmeier, MD | |
|
100 Professional Lane, Suite A, Enterprise, AL 36330 | |
| (334) 347-4018 | |
| (334) 347-0499 |
| Full Name | Mr Norman E Pahmeier |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 33 Years |
| Location | 100 Professional Lane, Enterprise, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619065083 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 00017088 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical Center Enterprise | Enterprise, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical And Surgical Eye Care Of Enterprise | 0143274449 | 2 |
News Archive
The U.S. Food and Drug Administration today approved a new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow's feet, in adults. Botox Cosmetic is the only FDA approved drug treatment option for lateral canthal lines.
REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.
Professor Kathryn North AM, the researcher responsible for discovering the ‘gene for speed', has been awarded the prestigious Ramaciotti Medal for Excellence in Biomedical Research and a $50,000 grant.
The U.S. Food and Drug Administration will seek comments on how to ensure that information on FDA activities and decision-making is useful, understandable, and accessible to the public, during a daylong public meeting on Nov. 3, 2009.
› Verified 7 days ago
| Entity Name | Medical And Surgical Eye Care Of Enterprise |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457449829 PECOS PAC ID: 0143274449 Enrollment ID: O20050309000828 |
News Archive
The U.S. Food and Drug Administration today approved a new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow's feet, in adults. Botox Cosmetic is the only FDA approved drug treatment option for lateral canthal lines.
REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.
Professor Kathryn North AM, the researcher responsible for discovering the ‘gene for speed', has been awarded the prestigious Ramaciotti Medal for Excellence in Biomedical Research and a $50,000 grant.
The U.S. Food and Drug Administration will seek comments on how to ensure that information on FDA activities and decision-making is useful, understandable, and accessible to the public, during a daylong public meeting on Nov. 3, 2009.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Norman E Pahmeier, MD 100 Professional Lane, Suite A, Enterprise, AL 36330 Ph: (334) 347-4018 | Mr Norman E Pahmeier, MD 100 Professional Lane, Suite A, Enterprise, AL 36330 Ph: (334) 347-4018 |
News Archive
The U.S. Food and Drug Administration today approved a new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow's feet, in adults. Botox Cosmetic is the only FDA approved drug treatment option for lateral canthal lines.
REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.
Professor Kathryn North AM, the researcher responsible for discovering the ‘gene for speed', has been awarded the prestigious Ramaciotti Medal for Excellence in Biomedical Research and a $50,000 grant.
The U.S. Food and Drug Administration will seek comments on how to ensure that information on FDA activities and decision-making is useful, understandable, and accessible to the public, during a daylong public meeting on Nov. 3, 2009.
› Verified 7 days ago